Lilly-Backed China Startup Debuts With $68.7M Seed to Advance Next-Gen T Cell Engagers

Excalipoint Therapeutics will use its seed money to advance a pipeline of cancer therapies, including a tri-specific antibody for small cell lung cancer and neuroendocrine tumors.